

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

GARY R. BRASLAWSKY, et al.

Group Art Unit: 1643

Application No.: 10/058,069

Examiner: David J. Blanchard

Filed: January 29, 2002

Confirmation No.: 2502

For: ENGINEERED TETRAVALENT ANTIBODIES AND METHODS OF USE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicants respectfully request the Examiner return an initialed copy of the enclosed Form PTO-1449 to Applicants with the next Office communication to indicate that the reference(s) has been considered, per MPEP § 609.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Please charge Deposit Account 033975 in the amount of \$180.00 in payment of the fee under 37 CFR 1.17(i)(p). Please credit or debit Deposit Account 033975 as needed to ensure consideration of the disclosed information.

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR 1.97(e)(1).

Respectfully Submitted,



Thomas A. Cawley, Jr., Ph.D.
Registration Number 40944
Customer Number: 00909

Date: April 6, 2006
PILLSBURY WINTHROP SHAW PITTMAN LLP
Telephone: (703) 770-7900
Facsimile: (703) 770-7901
P.O. Box 10500
McLean, VA 22102

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office					Atty. Dkt. No.	M#	Client Ref.
					037003	0280727	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Applicant: Gary R. Braslawsky		
					Appln. No.: 10/058,069		
Date: April 6, 2006					Filing Date: January 29, 2002		
Page 1					Examiner: David J. Blanchard		
					Group Art Unit: 1643		
U.S. PATENT DOCUMENTS							
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)	
	AR 6,060,273	05/09/2000	DIRKS et al.				
	BR						
	CR						
	DR						
	ER						
	FR						
	GR						
	HR						
	IR						
	JR						
FOREIGN PATENT DOCUMENTS							
	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available
					Enclosed	No	Enclose
	KR WO 98/11241	03/19/1998	PCT	VON HOEGEN et al.			
	LR						
	MR						
	NR						
	OR						
	PR						
	QR						
	RR						
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)							
	SR	Mielke et al., (22 June 2000) Stabilized, long-term expression of heterodimeric proteins from tricistronic mRNA, <i>GENE, An International Journal on Genes, Genomes and Evolution</i> , Elsevier (Darmstadt, DE), p. 108					
	TR	Kolb et al., (1997) Expression of a recombinant Monoclonal Antibody from a Bicistronic mRNA, <i>HYBRIDOMA</i> , Mary Ann Libert, Inc., Vol. 16 (No. 5), pp. 421-426					
	UR	Lo et al., (1998) Expression and secretion of an assembled tetrameric CH2-deleted antibody in <i>E. coli</i> , <i>Human Antibodies and Hybridomas</i> , ELSEVIER Science B.V. (Amsterdam) Vol. 3 (No. 3), pp. 123-128 - ABSTRACT					
	VR	Fussenegger et al (1997), Autoregulated Multicistronic Expression Vectors provide One-step Cloning of Regulated Product Gene Expression in Mammalian Cells, <i>Biotechnol. Prog.</i> , American Chemical Society and American Institute of Chemical Engineers, pp. 733-740.					
	WR	European Search Report , (Supplemental) March 16, 2006, EP 02 80 2572					
	XR						
Examiner					Date Considered:		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							